8-K/A: Esperion Reports Strong Q2, First Operating Profit

Esperion Therapeutics reports preliminary Q2 2025 financial results with significant revenue growth, achieving its first quarter of operating income from ongoing business, and securing key patent settlements.

Summary

• Esperion Therapeutics filed an amended 8-K to correct preliminary Q2 2025 financial results previously announced on August 5, 2025.
• Total revenue for Q2 2025 was $82.4 million, a 12% increase year-over-year compared to $73.8 million in Q2 2024.
• Excluding one-time settlement milestones from Q2 2024, total revenue grew 69% year-over-year.
• U.S. net product revenue for Q2 2025 increased 42% year-over-year to $40.3 million.
• The company achieved its first quarter of operating income from ongoing business, reporting approximately $7.1 million for Q2 2025, a significant improvement from $2.6 million in Q2 2024.
• Net loss for Q2 2025 was $(12.7) million, a substantial improvement from $(61.9) million in Q2 2024.
• Basic and diluted net loss per share for Q2 2025 was $(0.06), compared to $(0.33) in Q2 2024.
• Reached settlement agreements with three ANDA filers, preventing generic versions of NEXLETOL (bempedoic acid) from entering the market before 2040.
• Total retail prescription equivalents for NEXLETOL and NEXLIZET increased by approximately 10% sequentially from Q1 2025.
• The number of healthcare practitioners writing prescriptions for NEXLETOL and NEXLIZET exceeded 28,000 in Q2 2025.
• Royalty revenue from European partner Daiichi Sankyo Europe (DSE) increased 30% sequentially to $13.6 million, with over 500,000 patients reached.
• Expects sustainable profitability beginning in the first quarter of 2026.
• Full year 2025 operating expenses are reiterated to be in the range of $215 million to $235 million, including approximately $15 million in non-cash stock compensation.

Sentiment

Score: 8

Explanation: The filing presents a strong positive outlook with significant revenue growth in key product segments, achievement of operating income, and successful intellectual property protection. The path to sustainable profitability by Q1 2026 is a major positive. While the overall YTD revenue is down due to prior one-time milestones, the underlying business performance is robust. The preliminary nature of the results introduces a minor cautionary note, but the overall sentiment is highly favorable.

Positives

• Total revenue grew 12% year-over-year in Q2 2025 to $82.4 million, and 69% excluding one-time settlement milestones from the prior year.
• U.S. net product revenue showed strong growth of 42% year-over-year to $40.3 million.
• Achieved the first quarter of operating income from ongoing business in company history, reporting $7.1 million for Q2 2025.
• Net loss significantly improved to $(12.7) million in Q2 2025 from $(61.9) million in Q2 2024.
• Successfully settled with three ANDA filers, protecting NEXLETOL's patent exclusivity until 2040.
• Increased total retail prescription equivalents by 10% sequentially and expanded prescriber base to over 28,000 HCPs.
• Strong growth in European royalty revenue, up 30% sequentially to $13.6 million, with over 500,000 patients treated.
• Anticipates achieving sustainable profitability starting in Q1 2026.
• New marketing campaign 'Can't take a statin? Make NEXLIZET happen!' is establishing strong branding.

Negatives

• Total revenue for the six months ended June 30, 2025, decreased 30% year-over-year to $147.4 million, primarily due to one-time settlement agreement milestones received in the comparable 2024 period.
• Collaboration revenue decreased 7% year-over-year in Q2 2025 and 54% year-over-year for the six months ended June 30, 2025, due to the absence of large settlement milestones from 2024.
• Cash and cash equivalents decreased to $86.1 million as of June 30, 2025, from $144.8 million as of December 31, 2024.
• The financial results are preliminary and unaudited, subject to change upon completion of the company's financial closing procedures.

Risks

• Preliminary financial data is unaudited and based on management estimates, and actual financial results may differ materially.
• There is no assurance that actual financial results will not differ from these estimates, including as a result of final adjustments and other developments.
• Preliminary estimates should not be viewed as a substitute for interim financial statements prepared in accordance with GAAP and are not necessarily indicative of future results.
• Forward-looking statements involve estimates, assumptions, and uncertainties that could cause actual results to differ significantly.
• Risks detailed in the company's Annual Report on Form 10-K for the year ended December 31, 2024, and Quarterly Report on Form 10-Q for the quarter ended March 31, 2025, and subsequent SEC filings.
• Risk that the company's financial closing procedures may not be completed within the anticipated timeframe to timely file the Form 10-Q.
• Potential for serious adverse reactions including hyperuricemia (leading to gout), tendon rupture or injury, and hypersensitivity reactions (anaphylaxis, angioedema, rash, urticaria) associated with NEXLIZET and NEXLETOL.
• Not recommended for use during pregnancy unless benefits outweigh risks to fetus, and breastfeeding is not recommended due to potential for serious adverse reactions in infants.

Future Outlook

The company reiterates its expectation for full year 2025 operating expenses to be in the range of $215 million to $235 million, including approximately $15 million in non-cash expenses related to stock compensation. Based on the strength of its performance, the company now expects to achieve sustainable profitability beginning in the first quarter of 2026.

Management Comments

• "Our preliminary second quarter results reflect the strength of our commercial execution and the growing adoption of our bempedoic acid therapies in cardiovascular disease prevention."
• "With more than 15% sequential quarterly growth and 42% year-over-year quarterly growth in net U.S. product sales, we are delivering on our commitment to patients and shareholders alike."
• "The three recent ANDA settlements also demonstrate our commitment to protecting our intellectual property portfolio and reflect our belief in the strength of our patents."
• "As we continue to expand access to these life-saving therapies through improved payer dynamics and prepare to launch our consumer television ad on connected TV, such as Hulu and NBC Sports, we remain focused on driving sustained revenue growth."
• "In parallel, we are advancing our clinical pipeline and pursuing strategic portfolio expansion to shape the future of cardiovascular disease prevention worldwide."
• "Importantly, we delivered our first quarter of operating income from ongoing business and expect our continued growth and achievements to support sustainable profitability beginning in the first quarter of 2026. With strong momentum, we are moving forward with confidence."
• "As we advance our growing leadership in cardiovascular diseases, we are proud to welcome Robert Hoffman and Craig Thompson, both seasoned executives with a wealth of commercial and operational expertise, to our Board of Directors."

Industry Context

The company operates in the cardiovascular disease prevention market, specifically targeting patients with elevated LDL-C who are unable to take recommended statin therapy. The strong U.S. net product revenue growth and increasing prescription numbers indicate successful commercial execution and growing adoption of its non-statin therapies (NEXLETOL and NEXLIZET). The ANDA settlements are crucial for protecting intellectual property in the competitive pharmaceutical landscape, ensuring market exclusivity for its key products against generic competition until 2040. Global expansion efforts, particularly in Europe and Asia, demonstrate a strategy to diversify revenue streams and leverage international partnerships, aligning with broader trends of pharmaceutical companies seeking global market penetration for specialized therapies.

Comparison to Industry Standards

• The 42% year-over-year growth in U.S. net product revenue for NEXLETOL and NEXLIZET is a strong performance, indicating robust market penetration and demand for its bempedoic acid therapies, especially when compared to the typical single-digit to low-double-digit growth rates seen for established pharmaceutical products.
• Achieving the first quarter of operating income from ongoing business is a significant milestone for a biopharmaceutical company, particularly one focused on commercializing new medicines, as many companies in this sector remain unprofitable for extended periods during development and initial commercialization phases. This suggests effective cost management and increasing sales volume.
• The successful settlement of ANDA litigation, securing patent exclusivity until 2040 for NEXLETOL, provides a long runway for revenue generation without generic competition, a critical competitive advantage in the pharmaceutical industry where patent expiry is a major risk. This compares favorably to companies facing imminent generic challenges, which often see significant revenue declines.
• The sequential 10% increase in total retail prescription equivalents and expansion to over 28,000 prescribing healthcare practitioners demonstrates effective commercial strategy and physician adoption, which is a key indicator of market acceptance for new therapies, often outpacing the slower adoption curves seen for some novel drugs.
• The European partner, Daiichi Sankyo Europe, surpassing the 500,000-patient mark and contributing 30% sequential royalty revenue growth, indicates successful international market expansion and strong demand for NILEMDO and NUSTENDI, comparable to successful global launches by larger pharmaceutical firms.

Management Changes

Legal Proceedings

• Reached settlement agreements with three ANDA filers not to market generic versions of NEXLETOL (bempedoic acid) prior to 2040.

Stakeholder Impact

• **Shareholders:** Positive impact due to strong revenue growth, achievement of operating income, and a clear path to sustainable profitability. Patent settlements provide long-term intellectual property protection, reducing future competitive risks.
• **Patients:** Continued and expanded access to NEXLETOL and NEXLIZET, life-saving therapies for cardiovascular disease prevention, through improved payer dynamics and increased prescriber base.
• **Healthcare Providers (HCPs):** Increased education and support from the company's field reimbursement team, leading to greater confidence in prescribing NEXLETOL and NEXLIZET due to favorable reimbursement landscape.
• **Employees:** Positive outlook due to company growth and move towards sustainable profitability, potentially indicating job security and future opportunities.
• **Partners (Otsuka, Daiichi Sankyo Europe, HLS Therapeutics, Neopharm Israel, CSL Seqirus):** Continued collaboration and progress in global expansion, leading to increased royalty revenues and market penetration for the company's products in various territories.

Next Steps

• Complete quarter-end financial close process for Q2 2025.
• Include complete Q2 2025 results in the Quarterly Report on Form 10-Q.
• Launch consumer television ad on connected TV (e.g., Hulu, NBC Sports).
• Advance clinical pipeline and pursue strategic portfolio expansion.
• Otsuka Pharmaceutical Co., Ltd. (Japan partner) to pursue expected approval and National Health Insurance pricing in H2 2025.
• Technology transfer for manufacturing NILEMDO and NUSTENDI to DSE, with working capital benefits expected in 2025.
• Health Canada review of New Drug Submissions for NEXLETOL and NEXLIZET, with expected market approval in Q4 2025.
• Neopharm Israel (Israel partner) to pursue market approval of NEXLETOL and NEXLIZET in H1 2026.
• CSL Seqirus (Australia/New Zealand partner) to pursue expected market approval in Q4 2026 for NEXLETOL and NEXLIZET.

Key Dates

Recommendation

The filing demonstrates strong operational performance, marked by significant U.S. product revenue growth and the achievement of the company's first quarter of operating income from ongoing business. The successful ANDA settlements provide crucial long-term patent protection for its key product, NEXLETOL, until 2040, significantly de-risking future revenue streams. The clear guidance towards sustainable profitability beginning in Q1 2026, coupled with expanding global partnerships and increasing prescription volumes, indicates a positive trajectory for the company. While the results are preliminary, the underlying trends are robust and suggest a favorable investment opportunity for a seasoned investor.

Keywords

Esperion Therapeutics, ESPR, Q2 2025 Earnings, Financial Results, Bempedoic Acid, NEXLETOL, NEXLIZET, Cardiovascular Disease, LDL-C, Operating Income, ANDA Settlement, Patent Protection, Biopharmaceutical, Lipid-lowering, Statins